Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NightstaRx Ltd, a Biogen Company
This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Are willing and able to provide informed consent for participation in the study.
Have a clinical phenotype and confirmed genetic diagnosis of CHM.
Have active disease clinically visible within the macular region.
Are willing and able to undergo ophthalmic examinations once every 4 months for up to 20 months.
Have a BCVA better than or equal to 6/60 (20/200; decimal 0.1; LogMAR 1.0; 34-38 ETDRS letters) in at least one eye.
You may not be if
Have a history of amblyopia in the eligible eye.
Have any other significant ocular or non-ocular disease/disorder in the eligible eye which, in the opinion of the investigator, may put the subject at risk because of participation in the study, influence the results of the study or influence the subject's ability to participate in the study.
Have participated in an interventional research study in the past 6 months.
